154 related articles for article (PubMed ID: 14743459)
1. Development of prostate cancer treatment: the good news.
Denmeade SR; Isaacs JT
Prostate; 2004 Feb; 58(3):211-24. PubMed ID: 14743459
[TBL] [Abstract][Full Text] [Related]
2. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
3. What PCPs and geriatricians need to know about robotic prostatectomy and organ-confined prostate cancer.
Carlucci JR; Nabizada-Pace F; Samadi DB
Geriatrics; 2009 Feb; 64(2):8-14. PubMed ID: 19256581
[TBL] [Abstract][Full Text] [Related]
4. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
Milecki P; Kwias Z; Martenka DJ
Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam.
Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E; Lief J
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):34-40. PubMed ID: 17289288
[TBL] [Abstract][Full Text] [Related]
6. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
7. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
8. Technological advances in radiotherapy for the treatment of localised prostate cancer.
Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
[TBL] [Abstract][Full Text] [Related]
9. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
10. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
[TBL] [Abstract][Full Text] [Related]
11. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy.
Eggener SE; Roehl KA; Yossepowitch O; Catalona WJ
J Urol; 2006 Oct; 176(4 Pt 1):1399-403. PubMed ID: 16952643
[TBL] [Abstract][Full Text] [Related]
12. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Herbst RS; Bajorin DF; Bleiberg H; Blum D; Hao D; Johnson BE; Ozols RF; Demetri GD; Ganz PA; Kris MG; Levin B; Markman M; Raghavan D; Reaman GH; Sawaya R; Schuchter LM; Sweetenham JW; Vahdat LT; Vokes EE; Winn RJ; Mayer RJ;
J Clin Oncol; 2006 Jan; 24(1):190-205. PubMed ID: 16326753
[TBL] [Abstract][Full Text] [Related]
13. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Beyer DC; McKeough T; Thomas T
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
[TBL] [Abstract][Full Text] [Related]
14. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
15. Conventional treatments of localized prostate cancer.
Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer: how can a common disease be so controversial?
Kelly WK; Scher HI
Curr Opin Oncol; 1994 May; 6(3):318-31. PubMed ID: 8080862
[TBL] [Abstract][Full Text] [Related]
17. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry.
Cooperberg MR; Broering JM; Litwin MS; Lubeck DP; Mehta SS; Henning JM; Carroll PR;
J Urol; 2004 Apr; 171(4):1393-401. PubMed ID: 15017184
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer: a chronic illness.
Doyle-Lindrud S
Clin J Oncol Nurs; 2007 Dec; 11(6):857-61. PubMed ID: 18063544
[TBL] [Abstract][Full Text] [Related]
19. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
20. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]